Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea

What this study is testing ClinicalTrials.gov NCT07281196 ↗

Description as written by the study sponsor.

Semaglutide (a GLP-1RA) is approved for type 2 diabetes mellitus T2DM and obesity, but its effect on obstructive sleep apnea OSA remains unclear. To evaluate changes in Apnea-Hypopnea Index (AHI) after 1-week and 4-week semaglutide treatment in T2DM/obesity patients with OSA, we conducted a single-center real-world study (RWS) of 15 patients. Outcomes assessed included AHI, weight, BMI, blood pressure, blood glucose (fasting blood glucose, glycated albumin), liver function, blood lipids, waist circumference, and other metabolic parameters, to provide real-world evidence for semaglutide in OSA management.

Treatments tested

• Semaglutide Subcutaneous Injection Drug

  This study is a observational study and the treatments are based on the clinical practice. In the study, patients with treatments were recorded. According to the instructions of drugs, 1ml of the injection contains 1.34mg of semaglutide. Each pre-filled injection pen contains 2mg of semaglutide and is placed in 1.5ml of solution. This product should be injected once a week.